Creative Medical Technology (NASDAQ:CELZ) Trading 1.4% Higher – What’s Next?

Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ)’s stock price was up 1.4% on Monday . The stock traded as high as $2.32 and last traded at $2.17. Approximately 92,849 shares traded hands during trading, an increase of 54% from the average daily volume of 60,117 shares. The stock had previously closed at $2.14.

Analysts Set New Price Targets

CELZ has been the topic of a number of research analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of Creative Medical Technology in a report on Monday, December 29th. Wall Street Zen lowered shares of Creative Medical Technology from a “hold” rating to a “sell” rating in a report on Saturday, December 20th. One investment analyst has rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Reduce”.

Creative Medical Technology Stock Performance

The company has a fifty day simple moving average of $1.93 and a two-hundred day simple moving average of $2.44. The firm has a market capitalization of $8.47 million, a PE ratio of -0.88 and a beta of 1.94.

Creative Medical Technology (NASDAQ:CELZ) last released its quarterly earnings data on Friday, March 20th. The company reported ($0.80) earnings per share for the quarter, missing the consensus estimate of ($0.37) by ($0.43). The company had revenue of $0.00 million during the quarter. On average, equities analysts anticipate that Creative Medical Technology Holdings, Inc. will post -3.19 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Creative Medical Technology

An institutional investor recently bought a new position in Creative Medical Technology stock. Jane Street Group LLC acquired a new stake in shares of Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 30,205 shares of the company’s stock, valued at approximately $59,000. Jane Street Group LLC owned approximately 1.17% of Creative Medical Technology at the end of the most recent reporting period. Institutional investors and hedge funds own 1.42% of the company’s stock.

About Creative Medical Technology

Creative Medical Technology Holdings, Inc (NASDAQ: CELZ) is a clinical?stage biotechnology company focused on the development, manufacture and commercialization of exosome?based therapies derived from human bone marrow mesenchymal stem cells. The company’s proprietary exosome platform is being investigated for applications in regenerative medicine, aesthetic dermatology, wound healing and anti?inflammatory treatments. Creative Medical leverages cGMP manufacturing processes to produce sterile, cell?free exosome formulations designed to support tissue repair and cellular rejuvenation.

The company’s lead product candidates include XoFlo, an exosome enrichment product intended for use in musculoskeletal and soft tissue injuries, and specialized formulations targeting skin rejuvenation and scar reduction.